200 fully characterised iPSCs lines: Oct4, Nanog, Sox2, Tra-1-60 expression. Normal karyotype.
Our Alzheimer’s disease iPSC portfolio adds power to your studies by ensuring sufficient patient cell lines are analysed to avoid type 1 and type 2 statistical errors.
Our vision is to prevent Alzheimer’s disease from ever progressing to a stage where it exerts physical effects on the individual by identifying interventional approaches that target the latent disease using the right drug at the right time in the right patient.